Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

New and experimental HIV treatments news

Show

From To
European Commission Grants Marketing Authorization for Gilead’s Fixed-Dose Combination Descovy® (Emtricitabine, Tenofovir Alafenamide) for Treatment of HIV

Gilead Sciences, Inc. today announced that the European Commission has granted marketing authorization for two doses of Descovy® (emtricitabine and tenofovir alafenamide 200/10 mg and 200/25 mg; F/TAF), a fixed-dose combination for the treatment of HIV-1 infection. Descovy is Gilead’s second TAF-based therapy to receive marketing authorization in the European Union.

Published
25 April 2016
From
Gilead press release
ViiV Healthcare, Medicines Patent Pool Extend Licence for Dolutegravir to All Lower Middle-Income Countries

The Medicines Patent Pool (MPP) and ViiV Healthcare announced an extension of their current licensing agreement today to increase access to dolutegravir (DTG), a promising new antiretroviral, to cover all remaining lower middle-income countries. The amendment to the 2014 licence specifically allows generic medicine distribution in four countries with patents - Armenia, Moldova, Morocco and Ukraine - that were not covered in the initial agreement. MPP sub-licensees can now sell in countries that are home to 94% of people living with HIV in the developing world.

Published
25 April 2016
From
ViiV Healthcare press release
U.S. Food and Drug Administration Approves Descovy® (Emtricitabine, Tenofovir Alafenamide), Gilead’s Third TAF-Based HIV Therapy

-Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Descovy® (emtricitabine 200 mg/tenofovir alafenamide 25 mg, F/TAF), a fixed-dose combination for the treatment of HIV. Descovy is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older. Descovy is not indicated for use as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults at high risk.

Published
05 April 2016
From
Gilead press release
Long-acting oral antiretroviral MK-8591 could represent 'paradigm shift' in HIV treatment and prophylaxis

An investigational antiretroviral agent that maintains drug levels that are able to inhibit HIV up to six months after dosing could represent a “paradigm shift” in HIV

Published
01 April 2016
By
Michael Carter
Gene therapy snips HIV out of infected cells and makes uninfected cells resistant

For the first time, researchers have used a gene-editing technique already used to produce cells resistant to HIV infection to target HIV-infected cells. They have managed

Published
30 March 2016
By
Gus Cairns
Combination inhibitor BMS-986197 demonstrates good activity against HIV in early study

A long-acting bio-engineered molecule with a triple mechanism of action demonstrated potent antiviral activity and worked against HIV that developed resistance to any one of the three

Published
18 March 2016
By
Liz Highleyman
Maraviroc may work as PrEP in combination with another drug – but probably not by itself

Two studies presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2016) outlined the first findings from the NEXT-PrEP study, otherwise known as HPTN 069.

Published
03 March 2016
By
Gus Cairns
San Francisco HIV providers: What did you learn at CROI 2016?

The HIV community has a lot of information to digest after an annual CROI (Conference on Retroviruses and Opportunistic Infections) conference. BETA wanted to distill some of these important findings by asking some prominent San Francisco Bay Area providers to give us their take on the conference. We asked, “What did you find interesting? What did you find exciting? And, what did you learn?”

Published
03 March 2016
From
BETA blog
ABIVAX’s Novel Approach to Treat HIV Demonstrates Safety and Preliminary Anti-viral Activity in Phase IIa

ABX464 is an orally available therapeutic that blocks HIV replication through an entirely novel mechanism, i.e. the modulation of the biogenesis of viral RNA, and acts by targeting the Rev protein.

Published
02 March 2016
From
Abivax press release
Gilead Sciences Announces FDA Approval of Odefsey as HIV-1 Treatment in Certain Patients

Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Odefsey® (emtricitabine 200 mg/rilpivirine 25 mg/tenofovir alafenamide 25 mg or R/F/TAF) for the treatment of HIV-1 infection in certain patients.

Published
02 March 2016
From
Gilead press release
← First12345...90Next →

Filter by country